Drug Database
NA

nabilone (Canemes)

✓ Approved

AOP Health · CNR1

什么是 nabilone?

nabilone 是一种治疗药物,由AOP Health研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Canemes
公司AOP Health
分子靶点CNR1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

nabilone 作用于 1 个分子靶点:

CNR1cannabinoid receptor 1 (CNR, CB1A)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

相关研究文献

PubMedNature reviews. Chemistry2026-11-19

Aryl 'onium' compounds in the efficient and mild synthesis of arynes.

Damle Haripriya A HA, Stuart David R DR

Arynes are highly reactive intermediates that serve as synthetic linchpins to access molecular scaffolds with an arene core, including pharmaceuticals and agrochemicals. The earliest reactions to form arynes used widely available aryl halides and very strong bases and, therefore, have limited functional group tolerance. Consequently, for almost 50 years, the state-of-the-art reagents used to generate arynes have been o-trimethylsilylaryl triflates, which are prized for the mild conditions associated with their use, although their synthetic accessibility remains limited. In this Review, we discuss the renaissance of deprotonative methods to generate arynes with the emergence of aryl 'onium' reagents, a class of aryne precursors bearing a positively charged super-leaving group based on oxygen, sulfur, chlorine, bromine or iodine. The efficient and mild access to arynes provided by these nascent precursors has the potential to expand the impact of arynes in synthetic chemistry and beyond.

PMID 43052419
阅读全文 →
PubMedNature communications2026-11-19

Metabolic engineering and deep learning-driven protein engineering for N-Acetylneuraminic acid biosynthesis in Escherichia coli.

Wang Nan-Kai NK, Yue Song S, Chen Jin-Ping JP, Su Chang C et al.

N-Acetylneuraminic acid (NeuAc) is a sialic acid valued in pharmaceuticals and infant nutrition, and microbial synthesis offers a scalable route once the pathway's catalytic bottlenecks are relieved. We combine deep learning with metabolic engineering to build a high-titer NeuAc-producing E.coli strain. Modular pathway engineering reaches 1.25 g L-1 and pinpoints N-acetylglucosamine 2-epimerase (AGE) as the rate-limiting step. We develop DLCatalysis, a deep learning framework that predicts kcat Km-1 directly from protein sequence and substrate, and use it to mine AGEBf that lifts the titer to 6.84 g L-1. DLCatalysis-guided redesign of AGEBf and NeuBNm raises NeuAc to 9.27 g L⁻¹, and identifying and deleting exuT, a previously unannotated NeuAc transporter, blocks product reuptake. In 5-L fed-batch fermentation the optimized strain produces 85.5 g L-1, showing that AI-guided enzyme discovery can resolve the bottlenecks that have limited microbial NeuAc production.

PMID 43052267
阅读全文 →
PubMedBMC health services research2026-11-19

Factors impacting cost-effectiveness results: evidence from rare diseases listed in China's rare disease catalogues.

Wang Linning L, Yang Mengyu M, Wang Sida S, Gu Suqi S et al.

The primary objective of this study was to examine the association between potential influencing factors and cost-effectiveness results in rare disease cost-effectiveness analysis (CEA). This study collected 199 CEAs on diseases included in China's two batches of Rare Disease Lists. Using the cost-effectiveness conclusions (positive or negative) as dependent variables (DVs), four models were established for the DVs: Base (the economic conclusion reported in the original study), Scenario 1-3 (thresholds: WTP=$50,000/QALY, $100,000/QALY, and $150,000/QALY). Twenty-two influencing factors were extracted as independent variables (IVs). Point-biserial correlation and Chi-square tests were employed to examine the associations between the IVs and DVs. Under all four scenarios, univariate logistic regression, multivariate logistic regression, and stepwise regression were performed to assess the relationship between influencing factors and cost-effectiveness conclusions. This study analyzed a total of 199 published CEAs on rare diseases. The number of studies demonstrating positive cost-effectiveness conclusions was 57 (Base), 92 (Scenario 1), 64 (Scenario 2), and 53 (Scenario 3), respectively. Across the three logistic regression models, industry funding (a subcategory of funding type) showed consistent positive associations with favorable cost-effectiveness outcomes across multiple scenarios, while the prevalence rate was negatively associated with positive economic evaluation outcomes. Our findings demonstrate that a substantial proportion of rare disease CEAs yield positive cost-effectiveness outcomes, with industry sponsorship and low prevalence rates exhibiting statistically significant associations with these positive outcomes. These observations hold particular policy relevance for healthcare systems that utilize published comparative economic analyses to inform reimbursement decisions and insurance coverage frameworks for orphan drugs.

PMID 43053017
阅读全文 →
PubMedEnvironmental science & technology2026-11-18

Environmentally Relevant F-53B Exposure Triggers Ovarian Cancer Progression via C5aR1-Mediated Noncanonical Signaling: An Adverse Outcome Pathway (AOP) Underlying Hybrid EMT and Stemness.

Dong Sitong S, Wang Yuwei Y, Fang Shusen S, Ban Chuang C et al.

Significant gaps remain in the health risk assessment methodologies for the PFOS (perfluorooctanesulfonic acid) alternative 6:2 Cl-PFESA (6:2 chlorinated polyfluoroalkyl ether sulfonate, F-53B), which has been widely recognized as the alternative to PFOS in China. To address this research gap, our study integrated multidimensional techniques to mechanistically construct an Adverse Outcome Pathway (AOP) for F-53B-induced ovarian cancer progression. Our findings demonstrated that exposure to environmentally relevant concentrations of F-53B significantly enhanced the migratory and invasive capabilities of ovarian cancer cells. Within the AOP framework of F-53B-induced hybrid epithelial-mesenchymal transition (EMT) and enhanced tumor stemness, the upregulation of C5aR1─triggered by ERα acting as a noncanonical receptor of F-53B─constitutes the molecular initiating event (MIE). Following this MIE, the recruitment of β-arrestin1 and Src was induced, leading to the assembly of a C5aR1/β-arrestin1/Src signaling complex. This complex facilitated the binding of β-arrestin1 to β-catenin and drove the nuclear translocation of β-catenin, ultimately activating hybrid EMT and stemness of tumor cells. Administration of the C5aR1 inhibitor PMX205 effectively abrogated subsequent key events (KEs) caused by F-53B exposure. Through in vitro and in vivo validation, our study established an AOP framework that provides a novel perspective for evaluating the potential risk of PFAS substitutes in promoting cancer progression.

PMID 43048911
阅读全文 →
PubMedAnalytical methods : advancing methods and applications2026-11-18

A DoE-optimized QuEChERS-HRMS method for the simultaneous determination of pesticides and pharmaceuticals in dairy products.

Boti Vasiliki V, Kobothekra Vasiliki V, Nannou Christina C, Albanis Triantafyllos T

Pesticides and pharmaceuticals may co-occur as residues in milk, yet the two classes frequently differ in polarity and stability, so a single sample preparation condition rarely suits both and they are conventionally determined by separate, class-specific protocols. This study presents a QuEChERS-high-resolution mass spectrometry (HRMS) method that reconciles these conflicting requirements within one workflow for the simultaneous determination of ten pesticides and four pharmaceuticals in dairy products. Salting-out and clean-up options were first compared, showing that carbon-based clean-up is incompatible with the aromatic pharmaceuticals; the amounts of sodium acetate, PSA and acetic acid were then optimized by a design-of-experiments approach (Plackett-Burman screening followed by a central composite design and response-surface modelling), yielding a single acidified acetate/PSA condition, with residual matrix effects compensated by matrix-matched calibration. Validation in milk gave recoveries of 66-117% at 10 and 50 µg kg-1 (RSD ≤ 14.9%), coefficients of determination (R2) of 0.9915-0.9996 and limits of quantification of 2.7-25 µg kg-1. Application to 41 dairy products from the Greek market showed that quantifiable residues were infrequent; ketoprofen in two samples (up to 15.0 µg kg-1), trimethoprim and myclobutanil in one each, and coumaphos only at trace level, with the quantified veterinary-drug residues below their EU MRLs. By consolidating two compound classes that are usually determined by separate protocols into one DoE-optimized procedure that also permits retrospective suspect and non-target screening, the method provides a practical tool for dairy-safety monitoring.

PMID 43049679
阅读全文 →
PubMedPharmaceuticals (Basel, Switzerland)2026-11-18

RETRACTED: Shafiq et al. Development and Optimization of Tamarind Gum-β-Cyclodextrin-g-Poly(Methacrylate) pH-Responsive Hydrogels for Sustained Delivery of Acyclovir. Pharmaceuticals 2022, 15, 1527.

Shafiq Kanza K, Mahmood Asif A, Salem-Bekhit Mounir M MM, Sarfraz Rai Muhammad RM et al.

The journal retracts the article titled "Development and Optimization of Tamarind Gum-β-Cyclodextrin-g-Poly(Methacrylate) pH-Responsive Hydrogels for Sustained Delivery of Acyclovir" [...].

PMID 43046806
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多nabilone